Morehouse School of Medicine

EQBMED is a collaborative, community-based partnership to address diversity in clinical trials supported by grant funding from PhRMANEW HAVEN, Conn., Oct. 22, 2024 /PRNewswire/ -- Equitable Breakthroughs in Medicine Development (EQBMED), led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center (RCMI-CC) at Morehouse School of Medicine, and Vanderbilt University Medical Center, collaborates with communities to make clinical trial sites more accessible, promoting participation in clinical trials with communities of color and rural communities. Marking further progress toward creating a more equitable medical research landscape, EQBMED announces the selection of two local clinical trial sites in Texas: Community Action Corporation of South Texas (CACOST) in Alice, Texas, and UT Southwestern Medical Center in collaboration with Parkland Health and a network of nonprofit community-based clinics in Dallas, Texas. Continue Reading Equitable Breakthroughs in Medicine Development Expands its Support in Texas The selection of these sites is honing in on the community-focus of EQBMED, with CACOST being the first Federally Qualified Health Center (FQHC) in the program and Parkland as the third largest safety net hospital in the US. Both sites serve an important role in the Hispanic, Latino, and Rural communities, and will be the path to improving access to innovative clinical trials. "Our partnerships with CACOST, UT Southwestern, and Parkland are essential to EQBMED's community-centric approach to expanding clinical trial access. As a FQHC and a safety-net hospital, these organizations work specifically on addressing social and financial barriers to health, with important, trusted roles in their communities," said Marcella Nunez-Smith, MD, MHS, Associate Dean for Health Equity Research, and C.N.H Long Professor of Internal Medicine, Public Health, and Management at Yale University. "This collaboration strengthens our efforts to bring clinical trials to the community, and ultimately creating a more equitable landscape in medical research." "The population we serve has higher percentages of diabetes, obesity and poverty than any state in the nation. Our partnership with EQBMED and Yale School of Medicine's mentorship will help us build an infrastructure to take on clinical trials to address the health disparities in our community and pave the way for a more inclusive future in medical research," said Ann E. Awalt, Executive Director at Community Action Corporation of South Texas . Similarly, UT Southwestern and Parkland Health play a unique and pivotal role in their community by operating one of the busiest emergency rooms in the country and the largest Level III Neonatal Intensive Care Unit in the region. "As one of the largest safety net hospitals in the US, we're excited to embark on our partnership with EQBMED to identify trials that address the unmet needs of our community," said Kavita Bhavan, MD, MHS, Chief Innovation Officer at Parkland Health, Adjunct Professor at the UT Southwestern School of Medicine and Adjunct Professor at the Peter J. O'Donnell Jr. School of Public Health. "This partnership is a historical step forward in our work to include diverse populations in clinical trials by addressing mistrust and hesitancy, improving access, and reducing barriers by partnering with community-based clinics and integrating bilingual community health workers and navigators in the implementation of clinical trials for cancer, kidney disease, brain health, and cardiovascular disease among others," commented Heather Kitzman, PhD, Associate Professor in the Peter J. O'Donnell Jr. School of Public Health, and Director of the Office of Community Health & Research Engagement, Clinical and Translational Science Award at UT Southwestern Medical Center. EQBMED continues to build on the collaborative efforts of its network partners and community partners, working with communities who have historically been less engaged in the research and development of potentially life-saving medical interventions. The selection of these sites builds upon the goal to establish a replicable framework of local, connected, community-based clinical trial sites. Learn more about our efforts: About EQBMEDEquitable Breakthroughs in Medicine Development (EQBMED) is a pioneering partnership committed to transforming the landscape of clinical trials by advancing diversity, transparency, and knowledge. This collaborative partnership is led by Yale School of Medicine, Morehouse School of Medicine, the Research Centers in Minority Institutions Coordinating Center at Morehouse School of Medicine, and Vanderbilt University Medical Center, and supported by grant funding from PhRMA. By empowering community-based sites and addressing historical disparities, the program is dedicated to creating a more inclusive future in medicine development. Learn more at EQBMED.org. About UT Southwestern Medical CenterUT Southwestern, one of the nation's premier academic medical centers, integrates pioneering biomedical research with exceptional clinical care, public health and education. The institution's faculty members have received six Nobel Prizes and include 25 members of the National Academy of Sciences, 22 members of the National Academy of Medicine, and 14 Howard Hughes Medical Institute Investigators. The full-time faculty of more than 3,200 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in more than 80 specialties to more than 120,000 hospitalized patients, more than 360,000 emergency room cases, and oversee nearly 5 million outpatient visits a year. For more information, visit: . About Parkland HealthParkland Health is one of the largest public hospital systems in the country. Premier services at the state-of-the-art Parkland Memorial Hospital include the Level I Rees-Jones Trauma Center, the only burn center in North Texas verified for adults and pediatric patients by the American Burn Association and the American College of Surgeons Committee on Trauma and a Level III Neonatal Intensive Care Unit. The system also includes two on-campus buildings housing multi-specialty outpatient clinics – the Ron J. Anderson, MD Clinic and the Moody Outpatient Center, as well as more than 30 community-based clinics and numerous outreach and education programs. Parkland enriches the health and wellness of the communities it serves by providing compassionate care and advancing health equity. For more information, visit . About Community Action Corporation of South TexasCommunity Action Corporation of South Texas (CACOST) is a multiservice non-profit organization incorporated in 1971 with a mission to improve the lives of South Texans by providing high-quality healthcare, education, housing, and economic opportunities through various services and partnerships. With over fifty years of uninterrupted service across a sixteen-county service area, CACOST operates across three core divisions: early education, economic stability, and healthcare, providing a comprehensive, whole-person approach to care. Our early education programs include Early Childhood Intervention, Early Head Start, and Head Start Birth to Five. Our economic stability programs provide housing assistance, utility support, Meals on Wheels, and our community services block grant programs. CACOST has provided primary healthcare services since 1986 and became a Federally Qualified Health Center (FQHC) in 2003. Operating health centers across six of the sixteen counties in our agency's rural service area, CACOST is unwavering in its commitment to advancing its mission and adapting to the evolving needs of its communities. In recognition of its dedication to providing high-quality care, CACOST has been recognized by the Health Resources and Services Administration as a Health Center Quality Leader, placing in the top 10% of health centers nationwide for overall clinical performance. Additionally, CACOST is recognized as a Patient-Centered Medical Home (PCMH), reflecting its commitment to building strong, collaborative partnerships between patients and their care team. For more information, visit: . About PhRMAThe Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. PhRMA has convened thousands of stakeholders to explore a new potential infrastructure with diverse communities, health systems, and academia that seeks to show proof of concept for a network of connected, community-rooted and sustainable trial sites. PhRMA provided a grant to Yale University to support the creation and development of this initiative. Learn more about PhRMA's Equity Initiative at PhRMA.org/Equity. Contact: [email protected] SOURCE Equitable Breakthroughs in Medicine Development (EQBMED) WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BRIDGEWATER, N.J., Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies. The investment over 10 years is aimed at strengthening Centers of Excellence in clinical study diversity at Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine. Funding will be used to hire clinical research staff, establish infrastructure such as online chat services and pharmacy upgrades, create customized training programs, and more. Each of the Centers of Excellence have their own specific needs, which will help them harness their insights into the underrepresented communities they serve as they seek to increase representation and improve diversity in clinical studies. Lionel Bascles SVP, Global Head of Clinical Trials and Operations, Sanofi "At Sanofi, our mission is to chase the miracles of science to improve people's lives, and this means all people's lives, regardless of their race or ethnicity. By partnering with these three esteemed Historically Black College and University medical schools, we hope to facilitate new inroads to communities that have been underrepresented in healthcare for far too long. Increasing diversity and inclusion is essential to the research and development of medicines and vaccines for people of all backgrounds." Valerie Montgomery Rice, MD, FACOG President and CEO, Morehouse School of Medicine "Morehouse School of Medicine is exceptionally grateful to Sanofi for this investment in our clinical study diversity Center of Excellence. We look forward to a robust partnership as we work to increase diversity in clinical studies and develop advanced opportunities for researchers, leading to greater health equity. More diversity in clinical studies will ensure traditionally underserved populations receive the very latest cutting-edge therapeutic innovations." Sanofi is a global innovator in the Diversity, Equity and Inclusion space, including by pioneering the international effort A Million Conversations to examine trust gaps in the healthcare system. In the U.S., Sanofi and the National Association for the Advancement of Colored People (NAACP) announced a strategic partnership in July that is aimed at advancing health equity for Black and underserved communities. About Sanofi We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY Media Relations Sandrine Guendoul | + 33 6 25 09 14 25 | [email protected] Evan Berland | +1 215 432 0234 | [email protected] Timothy Gilbert | + 1 516 521 2929 | [email protected] Investor Relations Thomas Kudsk Larsen |+ 44 7545 513 693 | [email protected] Aliz é Kaisserian | + 33 6 47 04 12 11 | [email protected] Arnaud Delépine | + 33 6 73 69 36 93 | [email protected] Corentine Driancourt | + 33 6 40 56 92 21 | [email protected] Felix Lauscher | + 1 908 612 7239 | [email protected] Tarik Elgoutni| + 1 617 710 3587 | [email protected] Nathalie Pham | + 33 7 85 93 30 17 | [email protected] Sanofi Forward-Looking Statements This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. SOURCE Sanofi WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The Advil Pain Equity Course was piloted this summer at the Morehouse School of Medicine and reviewed by physicians and nurse practitioners around the country. One of the first pain equity courses for medical students is launching at the Morehouse School of Medicine this fall.The Advil Pain Equity Course was developed by the school and BLKHLTH, a nonprofit focused on health equity. The course aims to equip trainees with the knowledge and tools to understand and address racial health inequities in pain prevention, treatment and management.The course offers insights into fostering safe, trustworthy, transparent and empathetic patient-provider interactions. It also emphasizes how to address the unique preferences and needs of Black patients in pain. The course was piloted this summer with medical and physician assistant students at the historically Black medical school, who offered feedback on its content and structure. Additionally, the course was reviewed by physicians and nurse practitioners around the country.“We know students are future healthcare professionals, and what better time and opportunity to teach them about these concepts and skills than during their education,” Uché Blackstock, M.D., founder and CEO of Advancing Health Equity, told Fierce Healthcare. Blackstock is a 2024 Fierce 50 winner.Advancing Health Equity, a consulting firm that partners with healthcare organizations to foster equitable workplaces, is promoting the course. There are plans to expand the course to other medical schools in 2025, with the ability to customize each program.The inequitable diagnosis and treatment of pain is a public health issue, disproportionately impacting communities of color. A past Advil and Morehouse survey of 2,000 Americans found that 93% of Black individuals said pain impacts their daily life, and 83% said they have had a negative experience when seeking help for their pain.Amid COVID-19 and the Black Lives Matter movement, there has been a growing emphasis on health equity in medicine, Blackstock noted. While med schools began incorporating the topic in training to some extent, “I don’t know any school offhand that has focused curriculum and content about teaching students about this issue of pain inequity,” she said.Part of promoting the course is elevating this phenomenon to patients, so they understand “it’s not their fault and we can really do better by them,” while providers need to better listen to patients and not be dismissive of their experiences. “What I always say is the patients are the experts of their bodies,” Blackstock added.Blackstock came into medicine during a period where physician prescribing habits around pain medications were changing in light of the opioid epidemic. At the time, opioids were predominantly being overprescribed to white patients, she said. While some might argue that was a positive thing, sparing Black patients from addiction or overdose, Blackstock notes there is a darker side to that reality.“There is always trauma with not treating someone’s pain,” Blackstock said. Patients with untreated pain are more likely to develop depression and anxiety. They may not be able to go to work. And acute pain could become chronic, particularly if a diagnosis is missed.“We do know that with our arsenal of pain medications we have out there, including Advil, that it is possible to adequately treat patient’s pain,” Blackstock said.In 2023, Advil teamed up with BLKHLTH and Morehouse School of Medicine to launch the Advil Pain Equity Project, a multiyear initiative dedicated to promoting equitable and accessible pain relief. The first year of the project was focused on elevating the voices of patients in a storytelling campaign, “Believe My Pain.” The project offers digital tools and resources designed for patients and healthcare professionals, available at BelieveMyPain.com.Blackstock believes it would be a productive step for students to begin learning about pain equity even before they arrive at med school. “The earlier that we can get this information and these conversations to our future health professionals, the better,” Blackstock said.